Emerging Therapies for Noninfectious Uveitis: What May Be Coming to the Clinics

Overview

Journal J Ophthalmol

Publisher Wiley

Specialty Ophthalmology

Date 2014 May 29

PMID 24868451

Citations 11

Authors

Jose R Maya

Mohammad A Sadiq

Liz J Zapata

Mostafa Hanout

Salman Sarwar

Nithya Rajagopalan

Kathleen E Guinn

Yasir J Sepah

Quan Dong Nguyen

Affiliations

Soon will be listed here.

Abstract

Corticosteroids along with other immunomodulatory therapies remain as the mainstay of treatment tor all patients with noninfectious uveitis (NIU). However, the systemic side effects associated with the long-term use of these drugs has encouraged the development of new therapeutic agents in recent times. This review article discusses upcoming therapeutic agents and drug delivery systems that are currently being used to treat patients with NIU. These agents mediate their actions by blocking specific pathways involved in the inflammatory process. Agents discussed in this review include full or recombinant monoclonal antibodies against interleukins such as IL-17 (secukinumab), IL-l (gevokizumab), and IL-6 (tocilizumab and sarilumab), antibody fragments against inflammatory cytokines such as TNF- α (ESBA 105) and T-cell inhibitors such as fusion proteins (abatacept), and next generation calcineurin inhibitors (voclosporin). In addition, administration of immune modulatory therapies using methods such as iontophoresis (EGP-437) and intravitreal injection (sirolimus) for the treatment of NIU' uveitis has also been discussed.

Citing Articles

A Review of Ocular Drug Delivery Platforms and Drugs for Infectious and Noninfectious Uveitis: The Past, Present, and Future.

Conrady C, Yeh S Pharmaceutics. 2021; 13(8).

PMID: 34452185 PMC: 8399730. DOI: 10.3390/pharmaceutics13081224.

Recent advances in the management of non-infectious posterior uveitis.

Singh R, Sinha S, Saini C, Elbasiony E, Thakur S, Agarwal A Int Ophthalmol. 2020; 40(11):3187-3207.

PMID: 32617804 DOI: 10.1007/s10792-020-01496-0.

Subcutaneous repository corticotropin gel for non-infectious panuveitis: Reappraisal of an old pharmacologic agent.

Agarwal A, Hassan M, Sepah Y, Do D, Nguyen Q Am J Ophthalmol Case Rep. 2018; 4:78-82.

PMID: 29503933 PMC: 5757479. DOI: 10.1016/j.ajoc.2016.09.004.

Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Ratay M, Bellotti E, Gottardi R, Little S Adv Healthc Mater. 2017; 6(23).

PMID: 29034584 PMC: 5915344. DOI: 10.1002/adhm.201700733.

Management of noninfectious posterior uveitis with intravitreal drug therapy.

Tan H, Agarwal A, Lee C, Chhablani J, Gupta V, Khatri M Clin Ophthalmol. 2016; 10:1983-2020.

PMID: 27789936 PMC: 5068474. DOI: 10.2147/OPTH.S89341.

References

Nguyen Q, Ibrahim M, Watters A, Bittencourt M, Yohannan J, Sepah Y . Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect. 2013; 3(1):32. PMC: 3610181. DOI: 10.1186/1869-5760-3-32. View

Sehgal S . Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998; 31(5):335-40. DOI: 10.1016/s0009-9120(98)00045-9. View

Krishnadev N, Forooghian F, Cukras C, Wong W, Saligan L, Chew E . Subconjunctival sirolimus in the treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2011; 249(11):1627-33. PMC: 3183290. DOI: 10.1007/s00417-011-1694-9. View

Schultz C . Voclosporin as a treatment for noninfectious uveitis. Ophthalmol Eye Dis. 2013; 5:5-10. PMC: 3653814. DOI: 10.4137/OED.S7995. View

Phillips B, Wroblewski K . A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis. J Ophthalmic Inflamm Infect. 2011; 1(1):29-34. PMC: 3062775. DOI: 10.1007/s12348-010-0015-5. View

Thiel M, Wild A, Schmid M, Job O, Bochmann F, Loukopoulos V . Penetration of a topically administered anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the human eye. Ophthalmology. 2013; 120(7):1403-8. DOI: 10.1016/j.ophtha.2012.12.015. View

Dick A, Tugal-Tutkun I, Foster S, Zierhut M, Liew S, Bezlyak V . Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013; 120(4):777-87. DOI: 10.1016/j.ophtha.2012.09.040. View

Fel A, Aslangul E, Le Jeunne C . [Eye and corticosteroid's use]. Presse Med. 2012; 41(4):414-21. DOI: 10.1016/j.lpm.2012.02.001. View

Nussenblatt R, Byrnes G, Sen H, Yeh S, Faia L, Meyerle C . A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina. 2010; 30(10):1579-87. PMC: 3174007. DOI: 10.1097/IAE.0b013e3181e7978e. View

10.

Navarro-Millan I, Singh J, Curtis J . Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012; 34(4):788-802.e3. PMC: 3805022. DOI: 10.1016/j.clinthera.2012.02.014. View

11.

Reichert J . Which are the antibodies to watch in 2012?. MAbs. 2012; 4(1):1-3. PMC: 3338935. DOI: 10.4161/mabs.4.1.18719. View

12.

Hazlewood G, Barnabe C, Barr S, Martin L . Abatacept use after failure of multiple biologic agents in patients with severe rheumatoid arthritis. J Clin Rheumatol. 2012; 18(8):416-8. DOI: 10.1097/RHU.0b013e3182784833. View

13.

Truchetet M, Mossalayi M, Boniface K . IL-17 in the rheumatologist's line of sight. Biomed Res Int. 2013; 2013:295132. PMC: 3741932. DOI: 10.1155/2013/295132. View

14.

Chi W, Yang P, Li B, Wu C, Jin H, Zhu X . IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol. 2007; 119(5):1218-24. DOI: 10.1016/j.jaci.2007.01.010. View

15.

Furrer E, Berdugo M, Stella C, Behar-Cohen F, Gurny R, Feige U . Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci. 2008; 50(2):771-8. DOI: 10.1167/iovs.08-2370. View

16.

Gul A, Tugal-Tutkun I, Dinarello C, Reznikov L, Esen B, Mirza A . Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis. 2011; 71(4):563-6. DOI: 10.1136/annrheumdis-2011-155143. View

17.

Iannone F, Lapadula G . The inhibitor of costimulation of T cells: abatacept. J Rheumatol Suppl. 2012; 89:100-2. DOI: 10.3899/jrheum.120257. View

18.

Chi W, Zhu X, Yang P, Liu X, Lin X, Zhou H . Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008; 49(7):3058-64. DOI: 10.1167/iovs.07-1390. View

19.

Ottiger M, Thiel M, Feige U, Lichtlen P, Urech D . Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci. 2008; 50(2):779-86. DOI: 10.1167/iovs.08-2372. View

20.

Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel M, Kurz-Levin M, Zayed H . Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012; 35(8):1654-62. PMC: 3402269. DOI: 10.2337/dc11-2219. View